SEC Company Response from Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) (TNXP) — Dec 4, 2018
Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)
Date: Dec. 4, 2018 · CIK: 0001430306 · Accession: 0001615774-18-013773
AI Filing Summary & Sentiment
File numbers found in text: 333-227228
Show Raw Text
CORRESP
1
filename1.htm
A.G.P./Alliance Global Partners
590 Madison Avenue
New York, New York 10022
December 4, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
100 F St., NE
Washington, D.C. 20549
Attention: Irene Paik
RE:
Tonix
Pharmaceuticals Holding Corp. (the “Company”)
File No. 333-227228
Registration Statement on Form S-1
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and
Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, A.G.P./Alliance Global
Partners, as representative of the underwriters, hereby joins the request of the Company that the effective date of the above-referenced
Registration Statement be accelerated so that it will become effective at 8:30 a.m. Eastern Time on December 6, 2018, or as soon
thereafter as practicable.
Pursuant to Rule 460 under the Securities Act,
please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited to participate
in the distribution of the securities, as many copies of the proposed form of preliminary prospectus as appears to be reasonable
to secure adequate distribution of the preliminary prospectus.
The undersigned confirms that it has complied
with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied
with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the
above-referenced issue.
Very truly yours,
A.G.P./Alliance Global Partners
By: Tom Higgins
/s/ Tom Higgins
Title: Managing Director
1